等待开盘 05-12 09:30:00 美东时间
+2.745
+2.71%
Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to Brinsupri and Arikayce growth drivers.
04-08 19:08
Insmed says Phase 3b Arikayce data show symptom and culture gains in lung infection patients, analyst backs approval.
03-24 00:24
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
Insmed shares fall after brensocatib misses Phase 2b CRSsNP endpoints, prompting program discontinuation as analysts remain bullish on other assets.
2025-12-19 01:30
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
2025-10-31 01:40
(来源:蚌埠新闻网) 转自:蚌埠新闻网 2025年9月26日,长风药业股份有限公司正式启动全球公开发售,计划发行约4119.8万股H股,发售价定为每股14.7...
2025-10-09 11:21
(来源:医趋势) 复星医药再度将其炎症疾病管线资产对外授权。8月26日,公司公告称,将其候选药物FXS6837的中国以外权益授...
2025-08-29 14:30
(来源:研报虎) 本周新药行情回顾: 2025年8月11日-2025年8月17日,新药板块涨幅前5:北海康成(+35.6%)、基石药业(+32.6%)、德...
2025-08-18 10:47
当一笔6.45亿美元的创新药授权交易撞上子公司复宏汉霖235%的年内涨幅,复星医药(02196)的估值逻辑正在经历一场静默重构。 8月11日,复星医药一则公告震...
2025-08-15 09:23
原标题:现象级大药机会,被引爆 我们不止一次提到过呼吸疾病赛道的巨大机会,包括《一个超级大药机会,将被引爆》、《下一个现象级大药蓄势》、《一哥超预期,引爆重磅...
2025-08-14 07:54